Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of
Report (Earliest event reported): December 1, 2006
BIOPHAN
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
0-26057
|
|
82-0507874
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
file number)
|
|
(I.R.S.
Employer Identification No.)
|
150
Lucius Gordon Drive, Suite 215 West Henrietta, New York
14586
(Address
of principal executive offices) (Zip code)
(585)
214-2441
(Registrant’s
telephone number (including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
|
Item
5.02.
|
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers; Compensatory Arrangements of Certain
Officers
|
On
December 1, 2006, Stan Yakatan was elected to our Board of Directors. Mr.
Yakatan was elected by our incumbent Board of Directors to fill a vacancy
created by the resignation of Ross B. Kenzie. Mr. Yakatan will serve on the
Audit Committee of the Board of Directors.
Mr.
Yakatan is Chairman and Chief Executive Officer of Katan Associates, a private
company which he founded in May 1989 that provides advisory services and
strategic planning for companies in the life sciences industry. From June
2003
to August 2005, Mr. Yakatan was Chairman and Chief Executive Officer of Grant
Life Sciences, a publicly-traded company engaged in the research, development,
marketing, and sale of diagnostic kits for the screening, monitoring, and
diagnosis of diseases with emphasis on women's health, infectious diseases,
and
cancers. Mr. Yakatan continues to serve as a Director of Grant Life Sciences.
He
is also a Director of Response Biomedical Corp. and LifePoint, Inc. and of
several privately-held companies in the life sciences industry. From 1968
until
he founded Katan Associates in 1989, Mr. Yakatan held various senior executive
positions with New England Nuclear Corporation (a division of E.I. DuPont),
ICN
Pharmaceuticals, Inc., New Brunswick Scientific Co., Inc. and Biosearch.
Mr.
Yakatan is the Chairman of Biocomm Inc., a venture capital firm, and has
founded
and served as Chief Executive Officer of numerous entrepreneurial ventures
in
the biomedical and healthcare sectors. He has served as a strategic advisor
to
government agencies in Canada and Australia.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
BIOPHAN
TECHNOLOGIES, INC. |
|
|
|
| Date: December
7, 2006 |
By: |
/s/ Darryl
L.
Canfield |
| |
Darryl
L. Canfield |
| |
Chief
Financial Officer |